Original language | English |
---|---|
Pages (from-to) | 15-17 |
Number of pages | 3 |
Journal | The Lancet Oncology |
Volume | 16 |
Issue number | 1 |
DOIs |
|
Publication status | Published - 1 Jan 2015 |
Externally published | Yes |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Oncology, Vol. 16, No. 1, 01.01.2015, p. 15-17.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Expanded access programmes
T2 - Patient interests versus clinical trial integrity
AU - Lorigan, Paul
AU - Ascierto, Paolo A.
AU - Dummer, Reinhard
AU - Eggermont, Alexander M.
AU - Flaherty, Keith T.
AU - Garbe, Claus
AU - Gogas, Helen
AU - Hauschild, Axel
AU - Kefford, Richard F.
AU - Kirkwood, John M.
AU - Larkin, James
AU - Long, Georgina V.
AU - Maio, Michele
AU - McArthur, Grant A.
AU - Ribas, Antoni
AU - Robert, Caroline
AU - Schadendorf, Dirk
AU - Sondak, Vernon K.
AU - Wolchok, Jedd D.
AU - Hudson, Andrew M.
N1 - Funding Information: PL declares personal fees from Bristol Myers Squibb (BMS), Merck Sharp anf Dohme (Merck), GlaxoSmithKline, Roche, Novartis, Amgen, and Celgene outside the submitted work. PAA declares grants and personal fees from BMS, Roche Genentech, Ventana; personal fees and non-financial support from Merck, GlaxoSmithKline, Amgen and Novartis, all outside the submitted work. RD declares personal fees from Amgen, MSD, Novartis, grants and personal fees from BMS, Roche, outside the submitted work. AME reports personal fees from BMS, Merck, GlaxoSmithKline, MedImmune, outside the submitted work. KTF declares personal fees from GlaxoSmithKline, Roche, Novartis, and Merck all outside the submitted work. CG reports personal fees from Amgen, MSD, and Novartis, grants and personal fees from BMS, GlaxoSmithKline, Roche, outside the submitted work. HG reports personal fees from ROCHE, BMS, GlaxoSmithKline, MERCK, AMGEN, Novartis, outside the submitted work. AH reports personal fees for consultancies and presentations from Amgen, BMS, Celgene, Eisai, GlaxoSmithKline, MedImmune, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma, outside the submitted work. RFK reports institutional reimbursement from GlaxoSmithKline, Merck, BMS, Novartis and Roche for Advisory Boards, and institutional reimbursement from BMS for an educational grant all outside the submitted work. JMK reports grants from Prometheus, personal fees from BMS, Merck, and GlaxoSmithKline outside the submitted work. JL reports grants from Pfizer, Novartis, BMS, MSD, outside the submitted work. GVL reports personal fees from GlaxoSmithKline, Roche, Novartis, BMS, Amgen, Merck, for advisory board and steering committee participation, outside the submitted work. MM reports grants and personal fees from BMS, ROCHE, GlaxoSmithKline, MedImmune, outside the submitted work. GAM reports grants from Pfizer Celgene, outside the submitted work and personal fees from Provectus. AR reports fees for consulting with Amgen, Astellas, Genentech-Roche, GlaxoSmithKline, Merck, Novartis, Pierre Fabre with honoraria deposited into a UCLA account, and Stock ownership in Compugen, Flexus Bio and Kite Pharma. CR declares personal fees from Amgen, BMS, Novartis, Merck, Roche, and GlaxoSmithKline for occasional consulting activities, outside the submitted work. DS reports personal fees for consultancies and presentations from Amgen, BMS, GlaxoSmithKline, MSD/Merck, Novartis, Roche and Boehringer Ingelheim, outside the submitted work. VKS reports personal fees from Merck, Amgen, OncoSec, MabVax, Polynoma, Bristol-Myers Squibb, and GlaxoSmithKline, outside the submitted work. JDW reports personal consulting fees from Bristol-Myers Squibb, Merck and Medimmune and institutional grants from Bristol-Myers Squibb, Medimmune and GlaxoSmithKline. All are unrelated to the submitted work. AMH declares no competing interests.
PY - 2015/1/1
Y1 - 2015/1/1
UR - http://www.scopus.com/inward/record.url?scp=84927635228&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(14)71161-1
DO - 10.1016/S1470-2045(14)71161-1
M3 - Comment/debate
C2 - 25638540
AN - SCOPUS:84927635228
SN - 1470-2045
VL - 16
SP - 15
EP - 17
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 1
ER -